Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul 24;398(10297):299.
doi: 10.1016/S0140-6736(21)01380-5.

Tocilizumab in COVID-19 therapy: who benefits, and how?

Chengliang Yang  1 , Hedi Zhao  2
Affiliations
Comment

Tocilizumab in COVID-19 therapy: who benefits, and how?

Chengliang Yang et al. Lancet. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

CY is a former postdoctoral fellow at the University Health Network. We declare no competing interests.

Comment in

Comment on

References

    1. RECOVERY Collaborative Group Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–1645. - PMC - PubMed
    1. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe COVID-19 pneumonia. N Engl J Med. 2021;384:1503–1516. - PMC - PubMed
    1. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033–2040. - PMC - PubMed
    1. Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA. 2020;324:799–801. - PMC - PubMed
    1. Atallah B, El Nekidy W, Mallah SI, et al. Thrombotic events following tocilizumab therapy in critically ill COVID-19 patients: a façade for prognostic markers. Thromb J. 2020;18:22. - PMC - PubMed

Substances